ALPHAMAB ONCOLO.DL-000002 (F:3NK) — Market Cap & Net Worth
Market Cap & Net Worth: ALPHAMAB ONCOLO.DL-000002 (3NK)
ALPHAMAB ONCOLO.DL-000002 (F:3NK) has a market capitalization of $900.23 Million (€770.02 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #9250 globally and #1172 in its home market, demonstrating a -8.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALPHAMAB ONCOLO.DL-000002's stock price €0.80 by its total outstanding shares 968574697 (968.57 Million). See ALPHAMAB ONCOLO.DL-000002 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
ALPHAMAB ONCOLO.DL-000002 Market Cap History: 2019 to 2026
ALPHAMAB ONCOLO.DL-000002's market capitalization history from 2019 to 2026. Data shows change from $1.84 Billion to $900.23 Million (-10.34% CAGR).
ALPHAMAB ONCOLO.DL-000002 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALPHAMAB ONCOLO.DL-000002's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.10x
ALPHAMAB ONCOLO.DL-000002's market cap is 2.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.61 Billion | $146.02 Million | -$412.42 Million | 11.01x | N/A |
| 2022 | $1.46 Billion | $166.84 Million | -$325.72 Million | 8.76x | N/A |
| 2023 | $849.27 Million | $218.77 Million | -$210.59 Million | 3.88x | N/A |
| 2024 | $498.24 Million | $640.08 Million | $166.34 Million | 0.78x | 3.00x |
| 2025 | $1.19 Billion | $566.24 Million | -$113.94 Million | 2.10x | N/A |
Competitor Companies of 3NK by Market Capitalization
Companies near ALPHAMAB ONCOLO.DL-000002 in the global market cap rankings as of August 4, 2026.
Key companies related to ALPHAMAB ONCOLO.DL-000002 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
ALPHAMAB ONCOLO.DL-000002 Historical Marketcap From 2019 to 2026
Between 2019 and today, ALPHAMAB ONCOLO.DL-000002's market cap moved from $1.84 Billion to $ 900.23 Million, with a yearly change of -10.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €900.23 Million | -24.29% |
| 2025 | €1.19 Billion | +138.64% |
| 2024 | €498.24 Million | -41.33% |
| 2023 | €849.27 Million | -41.86% |
| 2022 | €1.46 Billion | -9.15% |
| 2021 | €1.61 Billion | -18.39% |
| 2020 | €1.97 Billion | +7.21% |
| 2019 | €1.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of ALPHAMAB ONCOLO.DL-000002 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $900.23 Million USD |
| MoneyControl | $900.23 Million USD |
| MarketWatch | $900.23 Million USD |
| marketcap.company | $900.23 Million USD |
| Reuters | $900.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more